2024 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Japan
Japanese firms prioritize expansion in the US market, exhibiting high rates of complex CNS and oncology R&D success. Back home, drug shortages continue for type 2 diabetes.
What's Behind Japan Firms' Higher Approval Rates In Challenging Oncology, CNS Areas?
Despite a global tendency for lower than average success rates from Phase I to approval in the challenging oncology and CNS areas, a recent Citeline study finds top Japanese pharma firms have relatively high rates in these two categories in the US. So what are the factors driving those differences?
Japan Faces GLP-1 Shortage As Off-Label Diet Use Surges
Despite repeated warnings by regulatory authorities and physicians’ associations, the demand for easy diet aids is impacting the supply of GLP-1 receptor antagonists in Japan.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.